Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $46.51 USD
Change Today -0.33 / -0.70%
Volume 690.3K
As of 4:15 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for novo-nordisk a/s-spons adr (NVO)

Novo Nordisk A/S uses little or no debt in its capital structure and may have less financial risk than the industry aggregate. Accounts Receivable are among the industry's worst with 49.21 days worth of sales outstanding. This implies that revenues are not being collected in an efficient manner. Last, Novo Nordisk A/S is among the most efficient in its industry at managing inventories, with only 262.04 days of its Cost of Goods Sold tied up in inventory.
View Balance Sheet In U.S. Dollar
Currency in
Millions of Danish Krones
As of:Dec 31
Dec 31
Dec 31
Dec 31
4 Year
Cash and Equivalents13,408.011,553.010,728.014,396.0
Short-Term Investments4,652.05,076.03,973.01,760.0
TOTAL CASH AND SHORT TERM INVESTMENTS18,060.016,629.014,701.016,156.0
Accounts Receivable9,349.09,639.010,907.013,041.0
Other Receivables1,766.02,388.04,267.04,487.0
TOTAL RECEIVABLES11,115.012,027.015,174.017,528.0
Prepaid Expenses935.01,033.01,110.01,222.0
Other Current Assets48.0931.01,521.030.0
TOTAL CURRENT ASSETS39,591.040,163.042,058.046,293.0
Gross Property Plant and Equipment35,525.036,726.044,037.047,484.0
Accumulated Depreciation-19,409.0-21,065.0-22,155.0-24,348.0
NET PROPERTY PLANT AND EQUIPMENT16,116.015,661.021,882.023,136.0
Long-Term Investments273.0228.0551.0856.0
Deferred Tax Assets, Long Term2,414.02,244.04,231.05,399.0
Other Intangibles1,489.01,495.01,615.01,378.0
Other Long-Term Assets4,815.05,878.0----
TOTAL ASSETS64,698.065,669.070,337.077,062.0
Accounts Payable3,291.03,859.04,092.04,950.0
Accrued Expenses7,109.08,377.08,937.021,559.0
Short-Term Borrowings351.0500.0215.0720.0
Current Portion of Long-Term Debt/Capital Lease4.0------
Current Income Taxes Payable1,171.0593.02,222.02,771.0
Other Current Liabilities, Total8,853.08,309.08,759.03,689.0
TOTAL CURRENT LIABILITIES20,779.021,638.024,225.033,689.0
Long-Term Debt502.0------
Pension & Other Post-Retirement Benefits439.0760.0688.01,031.0
Deferred Tax Liability Non-Current3,206.0732.0672.07.0
Other Non-Current Liabilities2,324.01,907.02,183.02,041.0
TOTAL LIABILITIES27,250.025,037.027,768.036,768.0
Common Stock580.0560.0550.0530.0
Retained Earnings37,111.039,001.041,137.041,277.0
Treasury Stock-24.0-17.0-21.0-11.0
Comprehensive Income and Other-219.01,088.0903.0-1,502.0
TOTAL COMMON EQUITY37,448.040,632.042,569.040,294.0
TOTAL EQUITY37,448.040,632.042,569.040,294.0
TOTAL LIABILITIES AND EQUITY64,698.065,669.070,337.077,062.0

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVO:US $46.51 USD -0.33

NVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $55.64 USD -1.22
Biogen Idec Inc $417.63 USD -7.98
Bristol-Myers Squibb Co $65.12 USD -0.93
Eli Lilly & Co $68.41 USD -2.18
Reckitt Benckiser Group PLC 5,800 GBp -25.00
View Industry Companies

Industry Analysis


Industry Average

Valuation NVO Industry Range
Price/Earnings 28.7x
Price/Sales 8.4x
Price/Book 18.6x
Price/Cash Flow 23.0x
TEV/Sales 6.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO-NORDISK A/S-SPONS ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at